{
    "clinical_study": {
        "@rank": "119393", 
        "arm_group": {
            "arm_group_label": "Hib/PRP-T vaccine", 
            "arm_group_type": "Experimental", 
            "description": "One dose, correspond to 0.5 ml, composed of:\nPRP-T 10ug NaCl 0.85%\nFrequency: 1 injection"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study was to know the safety of Hib/PRP-T vaccine and immediate\n      reactions within the first 30 minutes after injection."
        }, 
        "brief_title": "Safety of Hib Vaccine (Bio Farma)", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This trial was an open-label study, no randomization, and no placebo or control group. Total\n      25 young healthy adult (volunteers) followed this trial. The safety was assessed within 24\n      hours, 48 hours, 72 hours, and 28 days after injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult (age 18 - 40 years old)\n\n          -  Provision of written informed consent\n\n          -  Good health according to the clinical investigator\n\n          -  Willingness and ability to adhere to the regimen of the study\n\n        Exclusion Criteria:\n\n          -  Known not enrolled in other study\n\n          -  Pregnancy or lactation\n\n          -  Known or suspected allergy to any of the vaccine component (by medical history)\n\n          -  History of unusual reaction to any previous vaccination\n\n          -  Known or suspected immune deficiency, or use of medication that may influence the\n             immune system\n\n          -  Prior respiratory infection\n\n          -  Other vaccination during the study, or one week before (inactivated vaccine) or one\n             month (live vaccine) before the study\n\n          -  Acute febrile illness (temperature > 37.5 Celsius)\n\n          -  Present evidence of serious diseases demanding medical treatment\n\n          -  Any significant congenital or chronic disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977170", 
            "org_study_id": "Hib 0110"
        }, 
        "intervention": {
            "arm_group_label": "Hib/PRP-T vaccine", 
            "description": "Hib liquid vaccine", 
            "intervention_name": "Hib/PRP-T vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adults", 
            "Hib vaccines", 
            "Immunogenicity", 
            "Safety"
        ], 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bandung", 
                    "country": "Indonesia", 
                    "state": "West Java", 
                    "zip": "40161"
                }, 
                "name": "Hasan Sadikin Hospital"
            }
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Study of Hib Vaccine (Bio Farma)", 
        "overall_official": {
            "affiliation": "Faculty of Medicine UNPAD", 
            "last_name": "Kusnandi Rusmil, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Local and systemic reactions", 
            "measure": "Incidence rate of adverse event of Hib vaccine (Bio Farma)", 
            "safety_issue": "Yes", 
            "time_frame": "30 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977170"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Presence of serum of bactericidal activities after immunization.", 
                "measure": "To evaluate the antibody function serum using serum bactericidal activities test", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Local and systemic reaction", 
                "measure": "Incidence rate of adverse event of Hib vaccine (Bio Farma)", 
                "safety_issue": "Yes", 
                "time_frame": "28 hours, 48 hours, 72 hours, 28 days"
            }
        ], 
        "source": "PT Bio Farma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PT Bio Farma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}